Guido Kroemer is currently Professor at the Faculty of Medicine of the University of Paris Descartes, Director of the research team "Apoptosis, Cancer and Immunity" of the French Medical Research Council (INSERM), Director of the Metabolomics and Cell Biology platforms of the Gustave Roussy Comprehensive Cancer Center, Deputy Director of the Cordeliers Research Center, and Hospital Practitioner at the Hôpital Européen George Pompidou, Paris, France. He is also a Foreign Adjunct Professor at the Karolinska Institute, Stockholm, Sweden.
Prior to joining INSERM (1994), Guido Kroemer was Senior Scientist of the European Community at the Spanish National Research Council (CSIC), at the National Center of Molecular Biology (1990-1992) and at the National Center of Biotechnology (1993). Guido Kroemer did his post-doctoral training in the Collège de France, Nogent-sur-Marne (1988-1989) and at the University of Innsbruck, Austria, after receiving his PhD/MD degree at the same University in 1985. He also holds a PhD degree in Molecular Biology (Autonomous University of Madrid, 1992).
Guido Kroemer has made important contributions to medical research through his groundbreaking work in the fields of cell biology and cancer research. He is best known for the discovery that the permeabilization of mitochondrial membranes constitutes a decisive step in programmed cell death. Kroemer has explored the fine mechanisms of mitochondrial cell death control, the molecular pathways that explain the inhibition of cell death in cancer cells, upstream of or at the level of mitochondria, and the mechanisms that make cancer cell death immunogenic. His work has had far reaching implications for the comprehension, detection and therapeutic manipulation of cellular demise. According to a survey published in the European Journal of Clinical Investigation in December 2013 (43: 1339–1365) on “Influential biomedical researchers”, Guido Kroemer is the scientist who has published more highly cited papers as a last author between 1996 and 2011 than any other researcher in the world.
Guido Kroemer's contributions have been recognized with numerous awards, including the Monika Kutzner Prize of the Berlin-Brandenburg Academy of Sciences (1998), the Gallet & Breton Prize of the French Academy of Medicine (1999), the Descartes Prize of the European Union (2006), the Carus Medal of the German Academy of Sciences (2007), the Grand Prix Mergier-Bourdeix of the French Academy of Sciences (2007), the Lucien Dautrebande Prize of the Belgian Royal Academy of Medicine (2009), the Duquesne Prize of the French National League against Cancer (2010), the "Coup d'Elan" Prize of the Bettencourt-Schueller Foundation (2011) the Léopold Griffuel Prize of the French Association for Cancer Research (2012), an Advanced Investigator Award from the European Research Council (2013), and the Mitjavile Prize of the French Academy of Medicine (2014), the Galien Prize for Pharmacological Resarch (2015), the Grand Prix Claude Bernard of the City of Paris (2016), the Brupbacher Prize for Cancer Research (2017) and the ADPS Longevity Research Award (2018) among others.
Guido Kroemer currently serves on the Editorial Boards of Cell Death & Differentiation, Cell Research, EMBO Journal, EMBO Molecular Medicine, Molecular & Cellular Biology, and Science Signaling. Kroemer is also the Editor-in-Chief of four journals, Cell Stress, OncoImmunology, Microbial Cell, and Molecular & Cellular Oncology. He is member of the European Molecular Biology Organization (EMBO), German Academy of Sciences (Leopoldina), Austrian Academy of Sciences, Academia Europaea, European Academy of Sciences (EAS), European Academy of Sciences and Arts (EASA), European Academy of Cancer Sciences (EACS), and Institut Universitaire de France (IUF). He is the Director of the Paris Alliance of Cancer Research Institutes (PACRI), the Founding Director of the European Research Institute for Integrated Cellular Pathology (ERI-ICP), and the Founding President of the European Academy of Tumor Immunology (EATI).